FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
The FDA approved pembrolizumab on May 23, 2017, for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H), or mismatch repair deficient (dMMR) solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options and for the treatment of unresectable or metastatic MSI-H or dMMR colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. The FDA granted the approval based on an understanding of the biology of MSI-H/dMMR across different tumors along with the clinically important effects on overall response rate (ORR) observed in patients who were enrolled in 1 of 5 single-arm clinical trials. The ORR was 39.6% among 149 patients with 15 different tumor types (95% confidence interval, 31.7–47.9), with a 7% complete response rate. The duration of response ranged from 1.6+ months to 22.7+ months, with 78% of responses lasting ≥6 months. Overall, the adverse event profile of pembrolizumab was similar to the adverse event profile observed across prior trials that supported the approval of pembrolizumab in other indications. This approval of pembrolizumab is the first time that the FDA has approved a cancer treatment for an indication based on a common biomarker rather than the primary site of origin.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The potency of anti-PD-1 in the clinic was further proved by its recent, first-in-class FDA approval as a tissueagnostic therapy for any unresectable or metastatic tumors exhibiting microsatellite instability or deficient mismatch repair (62).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [62]
Citations
Cites
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645 · cited 3×
“MSI-H or dMMR is observed in many primary cancers (7).”
BackgroundTumor mutational burden and response rate to PD-1 inhibition
Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839
Classification and characterization of microsatellite instability across 18 cancer types
Hause, R. J., Pritchard, C. C., Shendure, J., & Salipante, S. J. (2016) · Nature Medicine · doi:10.1038/nm.4191 · Cited by 991
Bouffet, E., Larouche, V., Campbell, B. B., Merico, D., de Borja, R., Aronson, M., Durno, C., Krueger, J., Cabric, V., Ramaswamy, V., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.6552 · Cited by 857 · cited 1×
“A concern raised during the reviewof the application resulted in a requirement to conduct assessment of safety and activity in pediatric patients with central nervous system (CNS) malignancies, givenpublished literature reports of antitumor responses and cerebral edema following checkpoint inhibition (a different PD-1…”
BackgroundVenderbosch, S., Nagtegaal, I. D., Maughan, T. S., Smith, C. G., Cheadle, J. P., Fisher, D., Kaplan, R., Quirke, P., Seymour, M. T., Richman, S. D., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0332 · Cited by 772 · cited 1×
“The rate of MSI appears lower in the metastatic setting, with approximately 5% of colorectal cancers being MSIH (7, 10).”
BackgroundFirst FDA Approval Agnostic of Cancer Site — When a Biomarker Defines the Indication
Lemery, S., Keegan, P., & Pazdur, R. (2017) · New England Journal of Medicine · doi:10.1056/nejmp1709968 · Cited by 664 · cited 1×
“In addition to sharing a hypermutated phenotype, MSI-H cancers across different histologies share common histopathologic characteristics, including lymphocytic and other immune cell infiltration, medullary histology, and poorly differentiated histology (8).”
BackgroundSelf-citationYip, S., Miao, J., Cahill, D. P., Iafrate, A. J., Aldape, K., Nutt, C. L., & Louis, D. N. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3012 · Cited by 400 · cited 1×
“Conversely, some patients with MSH6 mutations, either germline or due to external causes including prior temozolomide, may not demonstrate MSI (20, 21) and therefore may be less likely to respond to treatment.”
Background
Research works printed but not linked: 3
- Full prescribing information: KEYTRUDA
- U.S. Food and Drug Administration, BLA 125514/S-14 approval letter
- U.S. Food and Drug Administration, 2014, In vitro companion diagnostic devices guidance for industry and Food and Drug Administration staff
Cited by
Bagchi, S., Yuan, R., & Engleman, E. G. (2021) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042020-042741 · Cited by 2,189
Mosele, F., Remon, J., Mateo, J., Westphalen, C. B., Barlesi, F., Lolkema, M. P., Normanno, N., Scarpa, A., Robson, M., Meric-Bernstam, F., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.014 · Cited by 1,186
“According to basket trials, patients with MSI-H and NTRK fusion-positive tumours treated with ICIs and TRK inhibitors are expected to provide benefit.(48,73) Some limited responses were observed in patients with EGFR- and METamplified metastatic gastric cancer (mGC) treated with cetuximab and crizotinib in prospective…”
BackgroundThe Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker
Jardim, D. L., Goodman, A., de Melo Gagliato, D., & Kurzrock, R. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.10.001 · Cited by 1,192
Regulatory mechanisms of PD-1/PD-L1 in cancers
Lin, X., Kang, K., Chen, P., Zeng, Z., Li, G., Xiong, W., Yi, M., & Xiang, B. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02023-w · Cited by 784
“…or metastatic NSCLC with PD-L1 positivity [325], metastatic urothelial carcinoma [326], cervical cancer [327], classical Hodgkin lymphoma [328], microsatellite-unstable or mismatch repair-deficient cancer [329], gastric cancer [330] and primary mediastinal large B-cell lymphoma [331], among others.”
BackgroundReview of precision cancer medicine: Evolution of the treatment paradigm
Tsimberidou, A. M., Fountzilas, E., Nikanjam, M., & Kurzrock, R. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102019 · Cited by 756
Metadata
- Authors
- Marcus, L., Lemery, S. J., Keegan, P., & Pazdur, R.
- Affiliations
- United States Food and Drug Administration (US)
- Corresponding author
- Marcus, Leigh
- Venue
- Clinical Cancer Research
- Published
- 2019-07-01
- Volume
- 25
- Issue
- 13
- Pages
- 3753-3758
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2915944698
- Cited by
- 1,176
- References
- 18
- Citations by year
- 2026: 106 · 2025: 129 · 2024: 145 · 2023: 192 · 2022: 188 · 2021: 220 · 2020: 153 · 2019: 41
- FWCI
- 62.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- HHS | U.S. Food and Drug AdministrationHHS | U.S. Food and Drug Administration (FDA) (n/a)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- pembrolizumab, microsatellite instability-high, mismatch repair deficiency, solid tumors, colorectal cancer, immune checkpoint inhibitors, FDA drug approval, overall response rate, adverse events, metastatic cancer
- MeSH terms
- Antineoplastic Agents, Immunological, Clinical Trials as Topic, Drug and Narcotic Control, Humans, Neoplasms, Prognosis, United States, United States Food and Drug Administration, Treatment Outcome, Drug Approval, Kaplan-Meier Estimate, Microsatellite Instability, DNA Mismatch Repair, Molecular Targeted Therapy, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-18-4070
- The paper
- Marcus, L., Lemery, S. J., Keegan, P., & Pazdur, R. (2019). FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-18-4070
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.